Business context and reporting period
Equillium, Inc. is a clinical-stage biotechnology company developing treatments for autoimmune and inflammatory diseases. This Form 10-Q covers the quarter and six months ended June 30, 2023. Its clinical-stage candidates are EQ101, EQ102 and itolizumab (EQ001). The company has no approved products and has generated no product-sales revenue.
Financial results and liquidity
| Metric | Three months ended June 30, 2023 | Six months ended June 30, 2023 |
|---|---|---|
| Revenue | $9.1 million | $18.0 million |
| Research and development expense | $9.6 million | $18.9 million |
| General and administrative expense | $3.1 million | $6.8 million |
| Operating loss | $3.6 million | $7.7 million |
| Net loss | $3.3 million | $7.3 million |
| Net loss per share, basic and diluted | $0.10 | $0.21 |
Revenue arose under the Ono Pharmaceutical asset purchase agreement: development-cost funding and recognition of part of the upfront payment, not product sales. The company recorded $6.8 million of development funding and $2.3 million of upfront-payment amortization in Q2. No revenue was reported in the comparable 2022 periods. Operating margins are not a useful measure of commercial performance at this pre-commercial stage.
- At June 30, cash and cash equivalents were $25.6 million and short-term investments were $22.8 million, totaling $48.4 million, versus $71.0 million at December 31, 2022.
- Six-month operating cash use was $14.2 million, compared with $23.4 million in 2022; Ono development funding contributed to the lower use. Investing cash use was $10.2 million, principally reflecting net purchases of short-term investments. Financing cash use was $9.0 million, primarily debt repayment.
- Working capital was approximately $32.1 million. The company repaid and terminated its term loan on May 25, 2023; it reported no notes payable at June 30.
- Accumulated deficit was $179.7 million. Stockholders’ equity was $27.0 million. The company had 34,568,500 common shares outstanding at June 30.
Material changes versus the prior comparable period
- Q2 revenue increased from zero in 2022 to $9.1 million in 2023, reflecting the Ono agreement. Six-month revenue was $18.0 million.
- Q2 net loss narrowed to $3.3 million from $14.1 million. For the first half, net loss narrowed to $7.3 million from $51.5 million, largely because the 2022 period included $23.0 million of acquired in-process R&D expense for the Bioniz asset acquisition, and 2023 included Ono revenue.
- Q2 R&D expense was broadly stable year over year; first-half R&D expense decreased to $18.9 million from $20.3 million. G&A expense also declined in both comparisons.
- Interest income rose to $0.6 million in Q2 and $1.3 million for the first half, versus $0.1 million in each comparable 2022 period, reflecting higher average interest rates.
Outlook, management commentary, risks and unusual items
- Management said June 30 liquidity, including after giving effect to the subsequent repurchase authorization, is expected to fund planned operations into 2025. The filing also states liquidity is expected to cover at least the next 12 months. These estimates depend on assumptions and may change with clinical costs, study timing, or other needs.
- Management expects significant future expenses and losses and does not expect product-sales revenue within the next 12 months, if ever. It may need additional equity, debt or partnership financing; financing may be unavailable, costly or dilutive, or require rights to be relinquished.
- Ono has an exclusive option to acquire Equillium’s itolizumab rights in the United States, Canada, Australia and New Zealand. If exercised, the stated option payment is approximately $34.8 million at the exchange rate cited in the filing, with up to $101.4 million in potential development and commercialization milestones. Exercise is not assured; Ono may terminate the agreement. Equillium continues to conduct and receive funding for development during the option period.
- Clinical milestones cited include EQ102 healthy-volunteer data and initial EQ101 alopecia areata data expected in the second half of 2023; EQ101 topline data expected in mid-2024; and anticipated 2024 data reviews for the EQUATOR aGVHD and EQUALISE lupus nephritis studies. Timing and outcomes are uncertain.
- In July 2023, the board authorized repurchases of up to $7.5 million of common stock through December 31, 2024; none had been made as of the filing. On August 7, the board approved repricing certain employee, officer and director options to the common-stock closing price on the effective date, subject to terms including an 18-month retention period. The incremental compensation cost was still being evaluated.
- Key risks include clinical failure or delay, reliance on Ono, Biocon and contract research and manufacturing organizations, need for additional capital, regulatory and supply-chain uncertainty, and potential adverse safety findings. The company disclosed that Nasdaq had notified it of noncompliance with the $1.00 minimum bid-price rule, with an October 2, 2023 deadline to regain compliance. It reported effective disclosure controls and no legal proceedings.
Important facts investors should verify
- Whether Ono continues funding the itolizumab program and ultimately exercises its option, and the timing and conditions for any option or milestone payments.
- Whether the company’s $48.4 million of cash and short-term investments supports its stated runway into 2025 after clinical spending, any share repurchases and other commitments.
- Progress, enrollment, safety and data timing for EQ101, EQ102, EQUATOR and EQUALISE; projected clinical timelines are not guarantees.
- The financial and dilution effects of the option repricing and any use of the $7.5 million repurchase authorization.
- Nasdaq bid-price compliance status and any subsequent notices, extensions or listing actions.